BiotechTube

Cefiderocol + Best Available Therapy

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthcare-associated Pneumonia (HCAP)

Conditions

Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)

Trial Timeline

Sep 7, 2016 → Apr 22, 2019

NCT ID
NCT02714595

About Cefiderocol + Best Available Therapy

Cefiderocol + Best Available Therapy is a phase 3 stage product being developed by Shionogi for Healthcare-associated Pneumonia (HCAP). The current trial status is completed. This product is registered under clinical trial identifier NCT02714595. Target conditions include Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP).

What happened to similar drugs?

0 of 2 similar drugs in Healthcare-associated Pneumonia (HCAP) were approved

Approved (0) Terminated (0) Active (2)
🔄Cefiderocol + Meropenem + LinezolidShionogiPhase 3
🔄Ceftolozane/tazobactam + MeropenemMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02714595Phase 3Completed

Competing Products

2 competing products in Healthcare-associated Pneumonia (HCAP)

See all competitors
ProductCompanyStageHype Score
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
40
Ceftolozane/tazobactam + MeropenemMerckPhase 3
40